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Abstract The high-risk strains of human papillomavirus
(HR-HPV) are known to be causative agents of cervical
cancer and have recently also been implicated in cancers of
the oropharynx. E6 is a potent oncogene of HR-HPVs, and
its role in the progression to malignancy has been
and continues to be explored. E6 is known to interact with
and subsequently inactivate numerous cellular proteins
pivotal in the mediation of apoptosis, transcription of tumor
suppressor genes, maintenance of epithelial organization,
and control of cell proliferation. Binding of E6 to these
proteins cumulatively contributes to the oncogenic poten-
tial of HPV. This paper provides an overview of these
cellular protein partners of HR-E6, the motifs known to
mediate oncoprotein binding, and the agents that have the
potential to interfere with E6 expression and activity and
thus prevent the subsequent progression to oncogenesis.
Introduction
Human papillomavirus (HPVs) are small, double-stranded
DNA viruses that preferentially infect epithelial tissues,
including those of the anogenital tract. It is also now
reported that a subset of these HPVs infect the oropharynx
[73]. Of the more than 100 different types of HPV that have
been identified, about 40 are involved in genital tract
infection. These HPVs can be classified as either high-risk
(HR) or low-risk (LR) depending upon the transforming
potential of the virus. Infection with LR-HPVs (HPV 6 or
11), for instance, can result in the proliferation of epithelial
cells, which manifests itself as warts or papillomas on the
skin. These symptoms, however, are generally self-limiting
and do not lead to malignancy. Once the virus has entered
its host through a disturbance in the epithelial barrier, the
principal targets of the virus are keratinocytes in the basal
layer of squamous epithelia [1, 50, 65, 74]. In infected cells,
the viral genome is either maintained as an episome or, in
rare instances, becomes integrated into the host genome,
where its life cycle becomes closely linked to the differ-
entiation course of the host cell. In general, benign tissues
display episomal viral DNA, while it is after DNA inte-
gration has taken place that HPV has the greatest potential
to induce oncogenicity. Although viral DNA integration is a
rare event, its occurrence may initiate a series of events
resulting in the genomic instability that can facilitate sub-
sequent cellular immortalization and transformation. In this
way, infection with HR-HPVs (HPV 16 or 18) may lead to
cervical intraepithelial neoplasia (CIN) in some women. In
fact, the HR strains 16 and 18 are present in[90% of cer-
vical cancer cases and have also been implicated in head
and neck squamous cell carcinomas, with HPV 16 being the
most common viral type [28, 41, 99].
Cancer is a major health concern in many developed
countries. In 2004, it was the second leading cause of death
in the US, following cardiovascular disease [55]. Currently,
HPV-induced cervical cancer is the second most common
cancer and the fifth leading cause of cancer-related deaths
among women worldwide [14, 73, 90]. Presently, there are
close to half a million cases of cervical cancer worldwide.
Due to these staggering statistics and in order to enable the
prevention of future HPV-induced cancers, companies such
as Merck and GlaxoSmithKline have developed HPV vac-
cines that have the potential to eliminate up to 70% of
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invasive cervical cancers and up to 90% of genital warts.
These prophylactic vaccines, however, are aimed at pre-
paring the immune system for possible future encounters
with the virus and cannot be used for the treatment of
already established virus infection or the cancers they cause.
HPVs have a genome that is divided into three regions:
an early region (E), a late region (L), and a non-coding long
control region (LCR). The E region encodes six non-
structural proteins: E1, E2, E4, E5, E6, and E7. The L
region encodes two structural proteins: L1 and L2. The E1,
E2, E4, and E5 proteins are required for viral DNA repli-
cation, the E6 and E7 proteins cooperate to transform and
immortalize cells, and the L1 and L2 proteins are needed
for the production of viral particles [68, 82]. As previously
mentioned, integration of HR-HPVs into the host cell
genome can result in genomic instability and immortali-
zation of the host cell. Viral DNA integration is often
accompanied by disruption of the E2 gene, and, less fre-
quently, of E1. The E2 protein is known to function, among
other things, as a transcriptional repressor of both E6 and
E7 expression. It has also been observed that the E1 gene is
frequently interrupted in carcinomas, suggesting that the
E1 gene product may also be a negative regulator of viral
transcription [95]. Because the E2 protein is a repressor of
E6 and E7 expression, the loss of E2 leads to an uncon-
trolled increase in the levels of these oncoproteins. The low
levels of E6 and E7 that are seen early in the normal viral
life cycle enable the initially low number of virus-infected
cells to survive and expand [30]. Once integration occurs
and levels of E2 drop, elevated levels of E6 and E7 can
result, which in turn enable cellular transformation. It
should be noted that many or most of these integration
events are likely to be non-productive, due to the loss of the
early region splice acceptor and polyadenylation sites
[109]. Most studies that employ over-expression of these
oncoproteins thus create conditions that are most analogous
to the latter set of conditions.
E6 and E7 together are effective in promoting the
immortalization of human foreskin keratinocytes in culture,
suggesting that they significantly contribute to the onco-
genic potential of HR-HPVs [80]. Results from numerous
studies demonstrate that interactions of E6 and E7 with the
tumor suppressor p53 and several members of the retino-
blastoma family proteins including pRb, p107, and p130,
respectively, lead to the inhibition of apoptosis and a
subsequent increase in the replication of transformed cells
[8, 33, 79]. In addition, interactions between HR-HPV
oncoproteins and endogenous cellular proteins have been
shown to trigger cell cycle deregulation, a critical com-
ponent in the progression to cancer [40]. Other research
results have reported on the significance of the viral
oncoprotein E6 from HR-HPVs in mediating cellular
transformation, supporting tumorigenesis, interfering with
epithelial organization, and activating telomerase. A thor-
ough understanding of the interactions of E6 with its
numerous cellular protein partners, as well as the conse-
quences of these interactions, allows for the possibility of
developing therapeutic approaches to impede the activity
of the oncoprotein.
The E6 oncoprotein
The HPV 16 E6 protein consists of 151 amino acids, with
two zinc fingers characterized by the CXXC motif.
Although it is a relatively short protein, E6 has proven
difficult to study due to the inability of the protein to be
isolated in a native, soluble form. E6 consists of a high
content of a-helical and b-sheet secondary structures. These
properties give rise to a protein that is both unstable and
insoluble once purified [86]. Recently, however, a model of
the structure of HPV 16 E6 has been proposed using an E6
mutant in which six non-conserved cysteines were replaced
with serine [87]. These substitutions not only allowed for
the purification of a soluble protein, but also produced a
protein that retained several tested biological activities of its
wild-type predecessor, including its ability to degrade p53
and to associate with its known protein partner E6-AP. The
availability of the three-dimensional structure of E6 allows
for the visualization of the potential residues that mediate
binding to its cellular protein partners. It is important to note
that the proposed model is based on the sequence homology
between the N and C-terminal halves of the protein and the
solved structure of the C-terminal domain of HPV 16 E6.
Some significant aspects of the native structure, such as the
interactions between the two domains and the structure of
the two domain boundaries, as well as the binding pocket
for leucine-rich peptides, therefore, remain incompletely
defined. However, although the derived structure may not
accurately model the E6 protein in all respects, it does
provide a framework for the potential development of
agents to specifically block interactions between E6 and its
protein partners. The validity of these agents would then
need to be further tested for biological significance in the
presence of the viral genome.
E6 is one of the earliest genes expressed following viral
infection and is one of two principal oncogenes of HPV,
along with E7. E6 was first classified as an oncogene when
in vitro and in vivo studies demonstrated that E6 expres-
sion can lead to hyperproliferation of cells, loss of
epithelial cell differentiation, and tumor formation. Addi-
tionally, studies with cervical tumors revealed that not only
is E6 expressed immediately following the initial trans-
formation, but expression is retained and can be detected
long after the transforming event [17, 77]. Expression of
the HR-E6 protein alone is sufficient to immortalize
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primary human mammary epithelial cells [6, 118], and E6
in cooperation with E7 can induce immortalization of
primary human foreskin keratinocytes in culture [48, 117].
Studies with LR-E6 reveal that these proteins cannot
induce the immortalization of these cells and are therefore,
inactive [48]. Progression to malignancy following viral
infection is thus reserved for HR-HPV strains.
To further substantiate these findings and to underline
the importance of E6 in HPV-induced carcinogenesis,
transgenic mice expressing the E6 protein have been gen-
erated. It has been found that formation of tumors is highly
dependent upon where the oncogene is expressed, as
expression of E6 in basal layers of squamous epithelium
leads to the development of squamous epithelial neoplasia
[4]. In addition, results from experiments with transgenic
mice expressing a mutant form of E6, unable to interact
with some of its cellular protein partners, revealed a sig-
nificant reduction in the ability of E6 to induce cervical
carcinogenesis [100]. Taken together, these data demon-
strate the potency of the oncoprotein E6 in contributing to
the malignant phenotype that may arise following suc-
cessful infection with HR-HPVs, such as HPV 16.
Protein partners of HPV 16 E6
The current literature provides us with abundant informa-
tion regarding cellular proteins to which E6 binds and
inactivates in order to support cell transformation. Most of
the cellular binding partners of E6 have been identified by
over-expressing these proteins in vivo. Therefore, although
binding has been determined for each of the protein part-
ners, the functional significance of many of these
interactions at normal expression levels requires further
evaluation. Nevertheless, results garnered from these over-
expression studies reveal that E6 interacts with a number of
different proteins that mediate the apoptotic pathway,
regulate transcription, and mediate chromosomal stability,
epithelial organization, differentiation, cell–cell adhesion,
polarity, and proliferation control in the infected cell
(Fig. 1). Interactions of E6 with these various proteins
contribute to the overall effectiveness of E6 in the pro-
motion of HPV oncogenicity.
Mediators of apoptosis
The first activity identified for HR-HPV E6 proteins was its
ability to form a complex with the tumor suppressor p53 in
vivo and to transform cells in vitro [119]. To avoid apop-
totic clearance, the E6 protein of oncogenic HPVs binds to
and inactivates p53, leading to its degradation and ablating
its ability to negatively regulate cell cycle progression.
Protein–protein interaction studies with E6 and p53 dem-
onstrate that E6 binding impedes the normal physiological
function of p53. Moreover, the E6-mediated inhibition of
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p53 activity facilitates the survival of transformed cells
[23, 67]. To determine whether the ability of E6 to mediate
p53 degradation is critical for the immortalization of
mammary epithelial cells (MECs), mutations that render
E6 unable to mediate p53 degradation were introduced into
the oncogene and tested. Dalal et al. report that p53 turn-
over is required for HPV-E6-induced immortalization of
MECs [24]. E6-mediated degradation of p53 requires the
formation of a trimolecular complex consisting of E6, the
100-kDa cellular E6-associated protein E6-AP, and p53.
The interaction between E6 and E6-AP gives rise to the
ubiquitin ligase moiety that directs p53 degradation
[98, 108].
In 1995, Pan and Griep reported that in p53-null mice
expressing the HPV 16 E6 protein, apoptosis was inhibited,
suggesting that E6 can also inhibit apoptosis by means
independent of p53 [89]. Indeed, E6 is now known to bind
to the pro-apoptotic protein Bak, mediate its degradation
via the proteasome, and reduce its ability to trigger apop-
tosis [111]. Similarly, E6 prompts the degradation of the
pro-apoptotic c-myc protein, resulting in sustained prolif-
eration of infected cells [57]. E6 can also exert its effects
on other apoptosis-related proteins at the transcriptional
level, as in the case of the anti-apoptotic protein survivin.
E6 is reported to significantly up-regulate survivin pro-
moter activity, giving rise to the suppression of apoptosis
[12]. Additional components of the host apoptotic
machinery to which E6 has been reported to bind include
the tumor necrosis factor receptor 1 (TNF R1) [34], the
adaptor molecule Fas-associated death domain (FADD)
[35], and procaspase 8 [36]. E6 binds to the death effector
domains (DEDs) of FADD and procaspase 8 and, in doing
so, mediates the accelerated degradation of both. Thus,
binding of E6 to these proteins make them unable to effi-
ciently participate in transmission of the apoptotic signal,
giving rise to the protection observed from apoptosis-
inducing stimuli.
Transcriptional regulation
In addition to the proteins that mediate apoptosis, E6 also
interacts with proteins involved in transcription control.
Yeast two-hybrid analyses, for instance, demonstrate that
E6 binds to E6TP1. E6TP1 exhibits high homology to
GTPase-activating proteins (GAPs) which are known to
function as tumor suppressors [37, 38]. In this way,
inactivation of E6TP1 by E6 may contribute to viral
oncogenesis. Results from similar experiments with
hADA3, the human homolog of yeast transcriptional
coactivator yADA3, show that E6 also binds to this protein
[52]. ADA3 is critical in the recruitment of histone
acetylases to promoter elements required for the expression
of tumor suppressor genes [120]. E6 binding to hADA3
therefore may result in the absence of these tumor sup-
pressors. Two-hybrid analyses also revealed the existence
of another E6 protein partner, tuberin, a TSC2 tumor
suppressor gene product. Tuberin is a component of the
molecular complex that negatively controls cell growth and
proliferation [114]. E6 binding to tuberin removes this
negative regulation, thereby permitting cell growth and
viral dissemination. Additionally, E6 influences cell cycle
progression by binding to the p53 co-activator CBP/p300,
resulting in decreased affinity of p53 for its DNA binding
site [121]. Yeast two-hybrid data reveals that HR-E6 binds
to Gps2 and targets it for degradation. Gps2 interacts with
CBP/p300 and facilitates its transcriptional regulation of
p53 [27, 92]; therefore E6 binding to both CBP/p300 and
Gps2 allows for the inappropriate survival and division of
infected cells. Interactions of E6 with this set of proteins
thus enhance the proliferation of virus-infected cells and
cumulatively add to the oncogenic potential of HR-HPVs.
Mediation of immune recognition
To further facilitate virus survival, E6 interferes with the
ability of the immune system to recognize infected cells
and to encourage their elimination. Yeast two-hybrid
experiments demonstrate that E6 interacts with interferon
regulatory factor-3 (IRF-3). IRF-3 normally mediates the
progression of apoptosis once a virus infection has been
detected by the immune system. E6 binding obstructs the
transactivation function of IRF-3, making it unable to
properly regulate the cell death pathway [17, 96]. Further,
toll-like receptors (TLRs) are important components of the
innate immune system. They primarily recognize the
pathogen-associated molecular patterns displayed by vari-
ous microbes and use them to generate signals that result in
the elimination of the pathogen by the host immune sys-
tem. Recently, it has been reported that E6 blocks the
transcription of the TLR9 gene in the cervical cancer cell
lines CaSki, SiHa, and HeLa [47]. This renders virus-
infected cells unable to undergo apoptosis, giving rise to
viral persistence in the host. These interactions of E6 with
its respective protein partners inhibit apoptosis and facili-
tate viral propagation, and may therefore contribute to
HPV-induced tumorigenesis.
Mediation of chromosomal stability
E6 has been shown to bind to the human minichromosome
maintenance seven protein, hMCM7, leading to chromo-
somal abnormalities in E6-expressing cells [61].
Association of the MCM complex with chromatin normally
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leads to the onset of eukaryotic genome replication. E6
inhibits this association by mediating MCM7 degradation
[77]. Loss of proper MCM7 function leads to the emer-
gence of chromosomal abnormalities in infected cells
which can contribute to carcinogenesis. Additionally, E6
interacts with and destabilizes O(6)-methylguanine DNA
methyltransferase and XRCC1, proteins involved in single-
strand DNA break repair [54, 103]. Binding of HR-E6 to
MCM7 leads to the development of chromosomal abnor-
malities which promote DNA damage. E6 interactions with
O(6)-methylguanine DNA methyltransferase and XRCC1
obstruct the ability of these proteins to repair the damages
incurred, giving rise to genomic instability in cells infected
with HPV. Thus, binding of E6 to these proteins cooper-
atively contributes to viral genome replication and viral
persistence. To avoid possible limitations in the prolifera-
tive capacity of these infected cells, HR-E6 increases
hTERT gene transcription, a telomerase-multi-subunit
complex that is responsible for synthesizing and adding
telomeric sequences to the ends of chromosomes, thereby
preventing DNA loss [59, 88, 93].
Mediators of epithelial organization and differentiation
Initial infection of HR-HPVs occurs in keratinocytes in the
basal layer of squamous epithelium. Following integration
of the viral genome into the host genome, viral DNA
replication takes place as the infected cells undergo dif-
ferentiation and cell division. Expression of the early
oncogenes allows the virus to successfully replicate in the
differentiated layers of the epithelium while also prevent-
ing the epithelial cells from undergoing terminal
differentiation. Since cell proliferation often requires
adhesion to an extracellular matrix (ECM), which would
hamper dysplasia, HR-HPVs have developed ways in
which to circumvent this problem.
Preservation of proper epithelial structure is important
for a cell to appropriately regulate its growth. Normal cell
division takes place when cells respond to proliferation
signals and terminate when the signal is removed or when
proper tissue size is reached. To overcome limitations in
cell proliferation, HR-E6 interacts with and subsequently
inactivates various proteins involved in epithelial organi-
zation. Paxillin, a protein that is associated with focal
adhesion proteins and is implicated in actin organization,
and thus in the maintenance of the cell cytoskeleton, has
been shown to bind HR-E6 [113]. Binding of E6 to paxillin
disrupts the formation of actin fibers, and it is this loss of
epithelial integrity that supports viral transformation.
Another key player in the promotion of cellular adhesion to
the extracellular matrix (ECM) is zyxin. Zyxin is a focal
adhesion molecule responsible for connecting the ECM to
the cytoskeleton, for regulating cell proliferation and dif-
ferentiation, for transmitting signals from the sites of cell
adhesion to the nucleus, and for organizing actin, along
with paxillin [26]. E6 binding to zyxin, in a manner similar
to paxillin, impairs the ability of these proteins to maintain
proper cell structure, which can lead to cellular transfor-
mation. Interactions between E6 and fibulin-1 have also
been reported to support cellular transformation and tumor
invasion by further contributing to the destabilization of the
ECM [31]. In addition, E6 and the calcium-binding protein
ERC-55 or E6-BP interact, resulting in the inability of
epithelial cells to undergo terminal differentiation [18].
Together, these activities reduce the ability of the infected
cell to adhere to the extracellular matrix and to sustain
normal cell morphology, and enhance its replicative
potential, thereby supporting cellular transformation and
the potential development of oncogenesis.
Mediators of cell–cell adhesion, polarity,
and proliferation control
The transformation and tumorigenic potential of HR-HPV
has been linked to the ability of the oncoprotein E6 to bind
additional proteins involved in mediating cell–cell adhe-
sion, polarity, and proliferation control. hScrib, the human
homolog of the Drosophila Scribble protein, behaves as a
tumor suppressor by negatively regulating cell growth. E6
has been reported to bind to hScrib and to mediate its
degradation, thus eliminating its control on cell cycle
progression [83]. hScrib is primarily found associated with
epithelial tight junctions, and loss of this protein leads to
the inability of cells to adhere to the ECM. In addition,
hDlg, the human homolog of the Drosophila disc large
tumor suppressor, is required for cell–cell adhesion, api-
cobasal polarity, and epithelial cell proliferation. HR-E6
binding to hDlg not only disrupts proper formation of cell–
cell junctions, but also leads to loss of cell polarity and cell
proliferation control [58, 70]. To further promote virus
survival, HR-E6 binds to and mediates the degradation of
PATJ [66, 105], which, like hScrib and hDlg, is important
in the proper formation of epithelial tight junctions in
polarized cells. HR-E6 also mediates the degradation of
PTPN3, a membrane-associated tyrosine phosphatase
involved in the phosphorylation of growth factor receptors
[56]. In this way, degradation of PTPN3 allows HPV-
infected cells to survive with less growth factor require-
ments. Together, binding of HR-E6 to these proteins gives
rise to the aberrant morphology characteristic of cancer
cells and supports the invasive growth of infected
keratinocytes.
High-risk strains of human papillomavirus have also
been shown to bind to other proteins that localize to the
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epithelial tight junctions, namely, MAGI-1, MAGI-2, and
MAGI-3 [29]. In addition, the MAGI-2 and MAGI-3 pro-
teins contribute to the regulation of the tumor suppressor
PTEN. Mutations in PTEN are commonly associated with
renal, breast, uterine, and advanced prostate cancers, sug-
gesting that PTEN may serve as a marker of tumorigenicity
for many cancers [16, 75]. MUPP1, like hScrib and hDlg,
plays a role in the negative regulation of cellular prolifer-
ation, and loss of its activity through E6 binding
encourages cell cycle progression and cell growth. The
MAGI proteins, along with the MUPP1 protein, are also
thought to play a role in signal transduction, and E6-
mediated inhibition of their activity may disturb the proper
formation of signaling complexes at the epithelial cell
membranes [77]. The ability of HR-HPVs to efficiently
transform cells and induce cellular proliferation, therefore,
relies in part on the ability of E6 to bind and inactivate
these numerous cellular proteins.
E6 binding motifs: domains that direct oncoprotein
binding
E6 binds to a number of cellular proteins that mediate
diverse activities in the cell, ranging from the regulation of
apoptosis to the maintenance of chromosomal stability.
Several attempts have been made to identify an E6 binding
motif or a sequence to which E6 preferentially binds to its
protein partners. In vitro and in vivo data demonstrate that
binding of E6 to p53, Bak, hMCM7, E6TP1, and c-myc is
facilitated by the E3 ubiquitin ligase moiety, E6-AP
[77, 78]. E6-AP is a 100-kDa cellular protein that, upon
interaction with E6, forms the complex necessary to
mediate the ubiquitination and subsequent proteasome-
mediated degradation of these proteins. Data from yeast
two-hybrid experiments incorporating a peptide library to
identify peptides that associate with E6 [32], data from
sequence comparisons of the known E6 binding partners
[7] and data from the use of inhibitory peptides to specif-
ically block E6 binding to these protein partners [72, 104]
reveal that E6 binds to a consensus sequence characterized
by the residues Lxx/Lsh [5] in which x represents any
amino acid, / is a hydrophobic residue, s is an amino acid
with a small side chain, and h is an amino acid that can
make multiple hydrogen bonding interactions with its side
chain (Fig. 2). In the case of E6/E6-AP interaction, the
seven-residue leucine-containing motif, LQELLGE, medi-
ates oncoprotein binding. This consensus sequence has also
been referred to as an LXXLL motif [20, 21] to highlight
the importance of the three conserved leucines at positions
9, 12, and 13 in facilitating E6 binding to its cellular
partners, as substitution of these leucines has been reported
to abolish E6/E6-AP interaction [7]. This same consensus
sequence in the E6-BP/ERC-55, IRF-3, paxillin, and tub-
erin proteins directs oncoprotein binding to this set of
partners. Once E6 has bound to E6-AP, the complex can
then bind to additional proteins and mediate their degra-
dation. Proteins in this group include p53, Bak, hMCM7,
E6TP1, and c-myc.
A comparison of the sequences of HR-HPVs reveals the
presence of a conserved C-terminal domain made up of the
residues XT/SXV, where X is any amino acid.
Motif to which E6 binds                       Cellular partners of E6                              References 
E6 binds directly to these proteins         E6-AP                                                            32, 53, 72
by way of the Lxx Lsh (or LXXLL)     32
motif                                                       IRF-3                                                             96
                                                                paxillin                                                          19, 113
                                                                tuberin                                                        5
                                                               
After E6 binds to E6-AP, the                  110
E6/E6-AP complex binds to                   c-myc                                                            57
these proteins                                          38
                                                                hMCM7                                                        60
                                                                p53                                                                81, 84, 104
PDZ domain                                           hScrib                                                           107
                                                                hDlg                                                              45
                                                                MAGI                                                           85
                                                                MUPP1                                                         66
                                                                PATJ                                                           8, 66, 79
                                                                PTPN3                                                          56                                
Unknown E6 binding motif                    FADD                                                           35
                                                                Gps2                                                           27
                                                                hADA3                                                          62
                                                                procaspase 8                                                  36
E6-BP/ERC-55                                              
Bak                                                                
E6TP1                                                           
Fig. 2 HR-E6 interacts with its
cellular binding proteins via two
known binding motifs, namely,
the Lxx/Lsh motif (or LXXLL
motif) and the PDZ domain.
However, the absence of these
motifs in the sequences of many
of its protein partners suggests
the existence of at least one
other motif that mediates
oncoprotein binding
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Interestingly, this sequence of amino acids is lacking in LR
strains of HPV [58]. This abbreviated stretch of residues
directs oncoprotein binding to the hDlg, hScrib, MUPP1,
PATJ, PTPN3, and MAGI proteins. The interaction of E6
with these proteins is mediated not by the seven-residue
leucine-containing motif, however, but by a conserved
PDZ domain, a region of *90 amino acids first recognized
in the sequence of a number of signaling molecules. PDZ-
containing proteins are often involved in signal transduc-
tion, transcriptional regulation, and cell polarity. Mice
expressing a version of E6 which lacks the C-terminal five
amino acids that mediate binding to the PDZ domain ren-
der these mice unable to trigger unregulated cellular
proliferation. This finding highlights the importance of the
PDZ domain in directing E6-induced hyperplasia [39, 69,
85]. Therefore, to date, two E6-binding motifs have been
identified (Fig. 2).
Interestingly, several of the known binding partners of
E6, including FADD, Gps2, hADA3 and procaspase 8, are
lacking both the LXXLL motif and the PDZ domain. This
suggests the existence of at least one additional binding
motif for the oncoprotein.
Inhibitors of E6 binding and therapeutic potential
At present, two vaccines have been developed for the
prevention of HPV-induced cervical cancer: a quadrivalent
vaccine, Gardasil, manufactured by Merck & Co., inten-
ded to prevent infection with the HPV strains 6, 11, 16, and
18, and a bivalent vaccine, Cervarix, manufactured by
GlaxoSmithKline, intended to prevent infection with
strains 16 and 18. These prophylactic vaccines are designed
to induce the generation of antibodies against the L1 and
L2 capsid proteins of HPV in the hopes that these anti-
bodies will neutralize future virus infection. These
vaccines, if administered before exposure to HPV, are
reported to be highly effective at protecting women from
infection [3, 106]. However, they are not therapeutic, and
papillomavirus infections often remain undetectable for
prolonged periods of time. Therefore, therapeutic vaccines,
designed to target the early non-structural proteins of the
virus, such as E6, may be more effective once infection has
occurred.
Successful infection with HR-HPV is usually accom-
panied by persistent expression of the E6 oncoprotein
[22, 97]. Interactions between E6 and its many cellular
binding partners contribute to viral propagation and the
possible progression to cancer. These characteristics have
therefore fueled the development of possible therapeutic
agents to treat already established HPV infections. Various
types of therapeutic vaccines are being developed that
target the early proteins of HR-HPV, especially the
oncoproteins E6 and E7, since these are continuously
expressed in cervical tumors. The vaccines that have been
generated include those that are viral/bacterial based [13,
49], peptide based [94], protein based [25, 63], or DNA
based [91]. If successful, these therapeutic vaccines have
the potential to treat HPV-associated premalignant tumors.
Unfortunately, such vaccines are expected to have
numerous limitations, including the loss of vaccine effec-
tiveness in individuals with a pre-existing viral immunity,
safety concerns when administering viral/bacterial based
vaccines, and the weak immunogenicity of peptide and
protein-based vaccines [76].
Therefore, a more in-depth understanding of the
molecular interactions of E6 that lead to oncogenesis is
being pursued, which will allow for the development of
additional approaches to either inhibit E6 expression or
combat the consequences that arise from E6 activity. For
example, the literature describes experiments to block
expression of E6 in HPV-positive cancer cells by inhibiting
viral transcription [43], by administering anti-sense con-
structs [46], and by administering RNAi targeting E6 [115]
in cell culture. The results obtained indicate that these
approaches can lead to an absence of detectable transcript,
an increase in the tumor suppressor p53 and a concomitant
increase in the induction of apoptosis, characteristics of a
more normal phenotype.
Once transcription has taken place and the E6 protein is
expressed, it has been shown that antibodies specifically
designed to target particular regions of E6 can be
successfully used to obstruct E6 activity [44]. Co-immu-
noprecipitation assays demonstrate that antibodies
generated to recognize epitopes in the N-terminus of E6
blocked E6 association with p53. Similarly, antibodies
generated to recognize the second zinc finger domain on
E6, which is required for E6-AP binding, blocked E6/E6-
AP association and prevented E6-mediated p53 degrada-
tion [64]. Monoclonal antibodies to the N-terminal ten
amino acids of E6 were shown to specifically bind to the
oncoprotein and inhibit proteolysis of p53 in HPV-16-
positive CaSki cells, as shown by immunoblot [42]. Peptide
aptamers, molecules designed to selectively bind to a given
target protein and block its activity in vivo, have been
effectively used to inhibit E6 binding to its respective
partners, resulting in increased p53 levels and the apoptotic
elimination of HPV-positive SiHa cells [15].
The identification of a conserved binding domain within
HPV 16 E6 binding partners, the LXXLL motif, has led to
the development of peptide inhibitors that harbor this motif
[11, 15]. Additionally, knowledge of the amino acids that
constitute the a-helical E6-binding motif has allowed for
the screening of chemical compounds harboring functional
groups necessary for binding E6. These compounds would
thus serve as chemical inhibitors of E6 binding to its target
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proteins in cells. Administration of these inhibitors has
been reported to competitively inhibit binding of E6 to its
natural partners, E6-AP and E6-BP, and thus interfere with
the ability of E6 to promote p53 degradation [5].
Interactions of E6 with PDZ-domain-containing proteins
are also important in facilitating the malignant progression
of HPV-infected cells. The residues on E6 necessary to
bind the PDZ domain localize to a small, exposed region
on the surface of the protein, suggesting that therapeutic
agents designed to block these interactions may be feasible
[112]. Moreover, knowledge of the amino acid sequences
that direct binding of HR-E6 to its protein partners further
contributes to the potential of developing agents that block
E6 binding to its cellular targets, resulting in the possible
re-sensitization of HPV-infected cells to normal cell-death-
inducing stimuli.
Conclusions
To survive and propagate in their host after infection,
viruses have developed varying strategies to avoid
immune clearance. Many viruses are able to manipulate
key components of the cell death pathway. These viruses
can produce homologs of cytokines, chemokines, or their
receptors that competitively bind to their respective cel-
lular partners, thereby preventing the generation of an
apoptotic signal [2, 9]. Members of the poxvirus family
produce soluble decoy receptors that obstruct the initial
ligand-receptor interaction at the cell membrane. The
cowpox virus, for instance, produces the TNFR-2 ortho-
logs, CrmB, CrmC, CrmD, and CrmE that bind to TNF
and inhibit initiation of apoptosis [101]. Further down-
stream, the bovine herpesvirus 4 (BHV4) produces the
BORFE2 protein intended to interact with the death
effector domain of caspase 8 and prevent the propagation
of the apoptotic signal from the Fas- or TNFR pathway
[116]. Similarly, the molluscum contagiosum virus
inhibits Fas-induced apoptosis when its MC159 protein
binds to cellular FADD [10, 102]. HPV also engages
mechanisms designed to escape elimination by the host.
The E6 and E7 oncoproteins of HPV interact with either
the tumor suppressor protein p53 [122] or pRb [71],
respectively, and in doing so, allow for cell cycle pro-
gression as well as resistance to apoptotic signals. It has
also been reported that E6 binds to the death effector
domains of FADD and procaspase 8 and that binding
leads to E6-mediated degradation of these proteins and
the resultant failure of HPV-expressing cells to undergo
apoptosis [35, 36]. Many different viruses have developed
mechanisms by which to disrupt the extrinsic arm of
apoptosis, suggesting that inactivating this cell death
pathway is integral for virus infection and survival.
High-risk strains of human papillomavirus are the
causative agents of cervical cancer and have recently been
found to be associated with *20% of cancers of the oro-
pharynx [51]. The HPV E6 protein is a fundamental
contributor to the oncogenic potential of the virus, and it is
its interactions with various cellular proteins that enable the
virus to persist. During the course of HPV infection, E6
binds and inactivates a number of key regulators of cell
cycle progression in order to permit infected cells to pro-
liferate. HR-E6 also blocks apoptosis by targeting p53,
Bak, c-myc, FADD and procaspase 8 for degradation.
Additionally, binding of E6 to E6TP1, hADA3, tuberin,
CBP/p300, and Gps2 hampers the ability of these proteins
to negatively regulate cell proliferation. HPV is also able to
suppress the innate immune system, through the binding of
E6 to IRF-3 and the E6-mediated down-regulation of TLR9
expression, making the immune system unable to recognize
and clear viral infection. Taken together, these interactions
collectively result in the deregulated multiplicity of virus-
infected cells.
Cancer cells are often associated with chromosomal
instability, DNA damage and a loss in the structural
integrity of epithelial cells. These factors allow cancer cells
to thwart the normal restrictions of cell division, thus
stimulating immortalization. E6 binding to hMCM7
promotes chromosomal instability, while binding to
O(6)-methylguanine DNA methyltransferase and XRCC1
prevents the repair of the DNA damage that arises from this
instability. To prevent possible limitations to cell cycle
progression, E6 stabilizes hTERT and up-regulates its
ability to catalyze the synthesis and addition of telomeres
to the ends of chromosomes. Heightened telomerase
activity allows for limitless proliferative capacity of HPV-
infected cells. In addition to these proteins, E6 also binds to
a specific group of PDZ-domain-containing proteins,
including hScrib, hDlg, MAGI-family proteins, MUPP1,
PATJ, and PTPN3. In this way, HR-E6 impairs the gen-
eration of appropriate cell–cell adhesion, polarity, and
proliferation control. Improper formation of focal adhe-
sions to the ECM, loss of proper cell polarity, loss of cell
cycle regulation, and the up-regulation of virus-infected
cell proliferation cumulatively contribute to the progres-
sion to malignancy.
Discovery of the numerous cellular binding partners of
HR-E6 has allowed for the identification of two binding
motifs or sequences which E6 preferably targets for inter-
action, the seven-residue leucine-containing motif, Lxx/
Lsh, and the PDZ domain. As mentioned previously, these
domains are absent in the sequences of FADD, Gps2,
hADA3, and procaspase 8, although binding of E6 to these
proteins has been shown. This suggests the existence of at
least one additional E6-binding motif. Current and future
studies on E6 and its cellular targets have significant
404 Arch Virol (2008) 153:397–408
123
implications for the development of possible therapeutic
approaches for cervical cancer as well as HPV-associated
head and neck cancers. The potential utilization of a multi-
pronged approach, including both prophylactic and thera-
peutic vaccines as well as molecular approaches to prevent
and treat HPV-positive cancers makes this an exciting time
for HPV-related studies.
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